Furthermore, a combinatorial therapy in preclinical models of breast cancer increased checkpoint inhibition by activating antigen-presenting cells, enhancing intratumoral CD8+ T cells, and increasing progenitor exhausted CD8+ T cells [61]. This evidence concerns the gene CD8A and breast carcinoma.